Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Muhammad Aamir Latif
- Target Recruit Count
- 121
- Registration Number
- NCT06888232
- Locations
- 🇵🇰
The Children's Hospital & Institute of Child Health, Multan, Punjab, Pakistan
Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
- Conditions
- Extramedullary Multiple Myeloma
- Interventions
- Biological: anti-BCMA/GPRC5D bispecific CAR-TDrug: Apornemin
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-03-13
- Target Recruit Count
- 20
- Registration Number
- NCT06793475
- Locations
- 🇨🇳
Beijing Gobroad Boren Hospital, Beijing, China
🇨🇳Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
Thalidomide Versus Argon Plasma Coagulation in Gastric Antral Vascular Ectasia(GAVE)-Related Anaemia in Cirrhosis (TAG Trial)
- Conditions
- Liver CirrhosisGastric Antral Vascular Ectasia
- Interventions
- Procedure: Argon Plasma Coagulation
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 100
- Registration Number
- NCT06772480
- Locations
- 🇮🇳
Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India
Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.
- Conditions
- Radiation Enteritis
- Interventions
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Yongquan Shi
- Target Recruit Count
- 150
- Registration Number
- NCT06617182
Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
- Conditions
- NK-LGL LeukemiaT-LGL Leukemia
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 48
- Registration Number
- NCT06530576
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia
- Conditions
- Fetal HemoglobinGenetic DiseaseThalassemia Major
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
- Target Recruit Count
- 54
- Registration Number
- NCT06490627
- Locations
- 🇵🇰
National Institute of blood disease and bone marrow transplant, Karachi, Sindh, Pakistan
Long Term Beta Thalassemia Treatment: Findings From The Extension Period
- Conditions
- Beta-ThalassemiaHemoglobinopathiesFetal Hemoglobin
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
- Target Recruit Count
- 30
- Registration Number
- NCT06490601
- Locations
- 🇵🇰
National Institute of blood disease and bone marrow transplant, Karachi, Sindh, Pakistan
Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor
- Conditions
- Yolk Sac TumorGerm Cell Tumor
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Shandong First Medical University
- Target Recruit Count
- 20
- Registration Number
- NCT06470464
- Locations
- 🇨🇳
Shandong Cancer Hospital and Institute, Jinan, Shandong, China
Thalidomide Therapy for VEOIBD
- Conditions
- Inflammatory Bowel Diseases
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Children's Hospital of Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT06382519
- Locations
- 🇨🇳
Lin Wang, Shanghai, Shanghai, China
Efficacy of Combination of Hdroxyurea and Thalidomide Over Either Hydroxyurea or Thalidomide Alone in the Treatment of Transfusion Dependent Thalassemia in Children: A Quasi-Randomised Clinical Trial
- Conditions
- Transfusion-dependent Thalassemia
- Interventions
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Target Recruit Count
- 90
- Registration Number
- NCT06299670
- Locations
- 🇧🇩
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.